Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 8 at 2:00 PM EDT

Register Free →

DoW Bone Marrow Failure, Resource Development Award

Active
HT942526BMFRPRDAGrant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The fiscal year 2026 Bone Marrow Failure Research Program Resource Development Award seeks to fund the creation of a comprehensive, open-access multioomic atlas derived from well-annotated human bone marrow failure samples, aiming to accelerate scientific and clinical understanding of these diseases. The initiative requires applicants to generate high-quality genomic, transcriptomic, proteomic, and clinical data integrated into a durable, universally accessible resource, with strict adherence to standardized metadata, data quality control, and robust data security practices. A central requirement is the submission of a detailed Data Resource Sharing Plan and a Sustainment Plan, ensuring the atlas remains available and operational beyond the award period through long-term maintenance strategies and archival in approved biomedical repositories. Applications must also include a Project Narrative, Statement of Work, Technical and Lay Abstracts, Data Management Plan, Impact Statement, and additional supporting documents, all formatted as individual PDFs with precise naming conventions and page limits, with the full application limited to a 12-page narrative, a 5-page SOW, and a 2-page sustainment plan among others. The award has a fixed funding cap of $1,250,000 with a maximum project duration of two years, and all submissions must be made through Grants.gov for extramural applicants or eBRAP for intramural Department of Defense entities, with the full application deadline set for November 4, 2026. Evaluation is based on a two-tier review system combining peer assessment of scientific merit with programmatic review of strategic alignment, emphasizing innovation, team expertise, multidisciplinary collaboration, and the potential for transformative impact on bone marrow failure research. While no formal FAR/DFARS clauses apply, compliance with DoD Instruction 3200.12, CDMRP data sharing directives, and regulatory approvals such as IRB/IACUC is mandatory. The award decision follows a trade-off process, enabling selection based on a balanced consideration of technical excellence, portfolio diversity, and sustainability potential rather than technical score alone. Applicants must maintain an active UEI in SAM.gov, include required representations, and ensure all personnel provide biographical sketches and current/pending support documentation, all of which must comply with federal research integrity and inclusion policies. No physical deliveries or FOB terms are involved; the entire performance scope centers on digital data generation, curation, and dissemination.

General Info

Funding supports creating open-access multiomic atlas from bone marrow failure samples for research.

Agency

Department Of Defense → Department Of The Army -- UsamraaView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(1)

FY26 Bone Marrow Failure Research Program Resource Development Award HT942526BMFRPRDA

PDFfunding-opportunity

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Department Of The Army -- Usamraa
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Defense → Department Of The Army -- Usamraa
View Agency Profile
Office AddressUS
Contacts
Christopher L BakerGrants Officer

Full Description

Show more

Summary: The fiscal year 2026 (FY26) Bone Marrow Failure Research Program (BMFRP) Resource Development Award (RDA) supports the development of a multiomic atlas generated from well-annotated human bone marrow failure (BMF) samples, with omic data derived from marrow specimens. The resulting dataset should serve as an open-access, durable resource for the BMF research and clinical communities and is expected to facilitate key discoveries that advance the understanding of BMF diseases.


Distinctive Features: The application must include a robust Data Resource Sharing Plan that describes the means and timeline by which the fully developed resource will be made available to the scientific and clinical community.

Similar Contracts

NAICS: 541714
New
Federal
RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)The Biomedical Advanced Research and Development Authority (BARDA), under the U.S. Department of Health and Human Services, is seeking proposals through Request for Proposal 75A50126R00002 to advance the late-stage clinical development and regulatory approval of 2-PAM autoinjectors as a drug/device combination product for the treatment of organophosphate poisoning, including nerve agents, in both adult and pediatric populations. The contract also encompasses the procurement of these autoinjectors for inclusion in the Strategic National Stockpile (SNS) and CHEMPACK programs. The solicitation requires offerors to demonstrate the capability to manufacture 600 mg 2-PAM autoinjectors at a Phase 3 clinical level or higher, with full FDA approval readiness. Proposals must include a comprehensive technical approach covering risk mitigation, project management, inventory control, and post-market surveillance, with mandatory compliance with current Good Manufacturing Practices and FDA guidance for emergency use or approved medical products. The contract features a base period of up to 36 months with up to three optional periods extending performance to a total of 10 years, involving a total potential procurement of 2 million adult-dose autoinjectors across four separate firm-fixed-price line items, each for 500,000 units, supported by cost-plus-fixed-fee line items for development and post-market activities. Deliveries are FOB destination to BARDA’s facility in Washington, D.C., with the contractor responsible for product integrity, temperature control (8–25°C), and security—including GPS tracking, tamper-resistant sealing, and TempTale documentation—until formal government acceptance. Evaluation is conducted on a best-value trade-off basis, with mandatory technical and infrastructure criteria serving as disqualifying thresholds, followed by technical approach, past performance, and cost. Offerors must be current in SAM with a valid UEI and CAGE code, and are subject to strict organizational conflict of interest disclosures, key personnel notification requirements, and prohibitions on the use of funds for abortions, needle distribution for illegal drug use, or human embryo research. Proposals must be submitted electronically via the BDR Portal by July 30, 2026, structured in three distinct volumes under strict page limits, with compliance to HHSAR and FAR clauses governing supply chain risk, anti-lobbying, and inspection standards.
Barda - Aspr / Daappo / Barda Dcma

POSTED

3 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Federal
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3The RAPIID program, specifically Task Area 3, aims to bridge the gap between lab-scale breakthroughs in shelf-stable blood analogs and real-world deployment by advancing the regulatory approval, manufacturing scalability, and field usability of components originally developed under the FSHARP program. These components, designed to replicate the critical functions of whole blood—oxygen delivery, hemostasis, and volume expansion—now require rigorous clinical validation to demonstrate safety and efficacy when used in combination, as well as scalable production processes to ensure consistent, high-volume output. Efforts under this solicitation will focus on pushing these technologies through the regulatory pathway to secure necessary approvals for military and civilian use in austere, pre-hospital environments. The initiative seeks to develop and scale enabling fielding technologies that support the deployment, storage, and administration of these blood analogs outside controlled laboratory settings. This includes not only the components themselves but also the logistical and operational frameworks needed to integrate them into frontline medical workflows. Proposals must address the full spectrum of challenges—from manufacturing robustness and regulatory compliance to usability in extreme conditions—while aligning with the program’s goal of delivering a complete, authorized system capable of saving lives where traditional blood supplies are unavailable. The solicitation, issued by DARPA’s Biological Technologies Office, has a response deadline of July 29, 2026, and is open to all qualified entities, targeting the NAICS code 541714 for research and development in physical, engineering, and life sciences.
Defense Advanced Research Projects Agcy

POSTED

3 days ago

DEADLINE

in 25 days
View Details
NAICS: 541714
New
Grant
NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is inviting applications for Disease Research and Translational Core Centers under the P30 mechanism, which is clinical trial optional. These centers aim to strengthen existing research institutions with established programs in cystic fibrosis, diabetes, nutrition, obesity, liver, and digestive diseases by fostering multidisciplinary collaboration, improving research rigor and reproducibility, and enhancing cost efficiency. The centers are structured around shared core services that provide access to specialized equipment, technical resources, analytical support, and expert-led training, all tailored to the specific needs of the research community within the institution. They also include a Pilot and Feasibility Grant Program to support new projects and a Scientific Catalyst Program administered through the Administrative Core, which promotes team building, mentoring, workshops, seminars, and visits by expert scientists to stimulate innovation and attract new investigators to the field. The program places strong emphasis on creating a nurturing environment for trainees and early-stage investigators, ensuring that emerging researchers benefit from mentorship and integrated scientific networks. Core services must be operated or overseen by recognized experts and are designed to be shared across center members to maximize impact and efficiency. The Scientific Catalyst Program specifically supports activities that build research capacity, encourage cross-disciplinary partnerships, and align scientific efforts with the center’s focus on chronic diseases. Applications are expected to demonstrate how the proposed infrastructure will enhance existing strengths and expand the institute’s research trajectory. The funding opportunity was posted on July 2, 2026, and inquiries should be directed to the designated NIDDK contact for further details.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

N/A
View Details